Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Identification of H2-Db and HLA-A2 Specific CD8 Epitopes from Human KDR/VEGFR-2 that Inhibit Angiogenesis by Vaccination

Posted Jun 15 2010 5:00pm

Description of Invention:
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2/KDR) is a promising target for cancer therapy due to its critical role in tumor associated angiogenesis and vascularization. This invention describes the amino acid sequences of seven short peptides based upon epitopes of human Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) that bind human Histocompatibility Leukocyte Antigen A2 (HLA-A2). These peptides can potentially induce Cytotoxic T Lymphocyte (CTL)-mediated lysis of tumor vascularization and inhibit tumor growth. The inventors have demonstrated the principles described in this invention in vivo in mice for VEGFR-2, using murine H2-Db specific peptides instead of HLA-A2. This invention has the potential to inhibit angiogenesis and may be applicable to tumor and autoimmune disease therapy.

Inventors:
Samir N Khleif (NCI)
Yujun Dong (NCI)


Patent Status:
HHS, Reference No. E-158-2005/0
US, Application No. 60/671,867 filed 15 Apr 2005
US, Application No. 12/402,401 filed 11 Mar 2009


Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.


Portfolios:
Cancer
Cancer - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Sabarni Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: chatterjeesa@mail.nih.gov
Phone: 301-435-5587
Fax: 301-402-0220


Ref No: 1127

Updated: 06/2010

Post a comment
Write a comment:

Related Searches